Phase I
Here’s a roundup of some of the top clinical trial news from the previous week.
Phase I clinical trial to evaluate safety and tolerability of ATR-002 in healthy volunteers
“ALS is a disease you really want to make a difference in,” Toby Ferguson Biogen’s senior medical director for Neuromuscular Research and Early Development told BioSpace.
In its first-quarter financial report, Solid Biosciences updated on its Phase I/II IGNITE DMD clinical trial. The progress was marred by adverse events.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Cambridge, Mass.-based Moderna announced publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0. They were both published in the journal Vaccine.
Auris Medical Holding Ltd. announced that it has reached the midpoint for enrollment in its Phase 1b proof-of-concept trial of AM-201, the Company’s investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.
PDC*line is a potent, scalable and versatile professional antigen-presenting T-cell with great potential for treating a range of cancers
Company is now preparing a Series B funding round to finance the Phase 2 clinical program
SMA is a severe neuromuscular disease caused by a mutation in the SMN1 gene, which codes for SMN, a protein necessary for motor neuron function.
PRESS RELEASES